Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-Congress-2020-1000x250

Media registration

ESMO welcomes media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card. Media representatives are required to observe and abide by the ESMO Media Policy which applies to all ESMO events.

Accredited journalists will have access to the ESMO official press conferences (as per timeline below), all congress sessions, the e-poster area, the virtual exhibition area, industry satellite symposia, and the congress webcasts.

The media accreditation process is closed, please refer to the ESMO Press Office (media@esmo.org) for any question.

ESMO Press Programme 

The following abstracts are currently included in the ESMO Press Programme and will be accompanied by a press release. The ESMO Press Programme is still under finalisation, and therefore changes may apply to this table. 

Please note that for some of them, the publication schedule may differ from the general one posted below. 

Upon publication, direct link to the press releases will be added. 

FPN 

Title 

Author Name 

Abstract Embargo Lift 

Press Release Distribution

LBA70_PR

The Impact of COVID-19 on Oncology Professionals: Initial Results of The ESMO Resilience Task Force Survey Collaboration

Banerjee 

Monday, 14 September 2020 at 00:05 CEST 

Monday, 14 September 2020 at 00:05 CEST 

Read more

LBA76_PR 

Expected medium and long term impact of the COVID-19 outbreak in Oncology

Jerusalem 

1581O_PR

Estimation of European cancer burden for the year 2020

Dyba

1613P_PR

An estimate of the 2-year oncology workload generated by each new patient: a real world study

Garattini

1678P_PR

The Impact of COVID-19 Pandemic on Cancer Care: A Global Collaborative Study

Jazieh 

LBA66_PR

Disparities in access to oncology clinical trials in Europe in the period 2009-2019

Carneiro

Friday, 18 September 2020 at 00:05 CEST

Friday, 18 September 2020 at 00:05 CEST

Read more

1588MO_PR

A comparative study on costs of cancer and access to medicines in Europe

Wilking

696O_PR

Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase 3 CheckMate 9ER trial

Choueiri

Saturday, 19 September 2020 at 00:05 CEST

Saturday, 19 September 2020 at 18:30 CEST

Read more

LBA3_PR

An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement. Primary end-point analysis of Lung ART (IFCT-0503, UK NCRI, SAKK) NCT00410683 

Le Pechoux

Saturday, 19 September 2020 at 00:05 CEST

Sunday, 20 September 2020 at 18:30 CEST

Read more

LBA5_PR

Abemaciclib in high risk early breast cancer

Johnston

Saturday, 19 September 2020 at 00:05 CEST

Sunday, 20 September 2020 at 18:30 CEST

Read more

LBA6_PR

Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the checkmate 649 study

Moehler 

Saturday, 19 September 2020 at 00:05 CEST

Monday, 21 September 2020 at 18:30 CEST

Read more

LBA7_PR

Nivolumab with chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric or gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study

Boku 

LBA8_PR

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as First-Line Therapy in Patients With Advanced Esophageal Cancer: The Phase 3 KEYNOTE-590 Study

Kato

Third-party media activities

Media activities initiated by third parties during or in connection with the event are subject to the ESMO Policy on Third-Party Media Activities which aims to guarantee proper and correct distribution of oncology and cancer-related information to media representatives in connection with the event. Such media activities include (but are not limited to):

  • Meetings such as press conferences, media briefings and educational sessions involving media representatives
  • PR activities, such as press releases, news, articles, interviews, etc.

Press events concomitant with/or during breaks of the scientific programme of the event are subject to ESMO Press Office approval.

Please submit your request by contacting the ESMO Press Office at  media@esmo.org.

Blackout times

During Blackout times any media activity initiated by third parties is not allowed.

Saturday 19 September 2020 from 11:00 to 20:00 CEST
Sunday 20 September 2020 from 12:30 to 20:00 CEST
Monday 21 September 2020 from 12:30 to 20:00 CEST

Friday 16 October 2020 from 10:30 to 17:30 CEST
Saturday 17 October 2020 from 10:30 to 17:30 CEST
Sunday 18 October 2020 from 10:30 to 17:30 CEST

All third parties wishing to hold media events are kindly requested to adhere to the specific media policy and be in contact through media@esmo.org.

Publication schedule for accepted abstracts

Data and information included in accepted abstracts is under embargo until the relevant embargo release date cited in the schedule below. 

Data and information beyond what is included in all accepted abstracts, including full data sets and full manuscripts, may only be made public at the start of the official programme session during which the study is presented. 

Abstracts

Date and time

Abstracts accepted as:

  • Poster (suffix ‘P’)
  • Poster (Trial in Progress) (suffix ‘TiP’)
  • EONS Poster (prefix ‘CN’)

Monday, 14 September 2020
00:05 Central European Summer Time (CEST)

Abstracts and late-breaking abstracts accepted as:

  • Mini Oral (suffix ‘MO’)

Friday, 18 September 2020
00:05 Central European Summer Time (CEST)

Abstracts and late-breaking abstracts accepted as:

  • Proffered Paper (suffix ‘O’)
  • EONS Proffered Paper (prefix ‘CN’)

Saturday, 19 September 2020
00:05 CEST (Central European Summer Time)

Abstracts and late-breaking abstracts selected for inclusion in the ESMO Press Programme (suffix ‘PR’)

Published according to a dedicated schedule to be made available by early September.

Contact

ESMO Press Office
E-mail: media@esmo.org

Press release distribution

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings